This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.
WASHINGTON (AP) — The latest pill for hepatitis C sounds like a difficult choice.
Sovaldi cures the liver-wasting illness in 9 of 10 patients, but treatment can cost more than $90,000.
Leading medical societies recommend Sovaldi. Patients clamor for it. But insurance companies and state Medicaid programs are gagging on the price. Officials in one state are proposing to limit how many low-income patients can get Sovaldi.
Yet a new pricing survey indicates that if Sovaldi didn't exist, insurers would still be paying in the mid-to-high five figures to treat the most common kind of hepatitis C.
And some of the older alternatives they would be buying expose patients to more side effects, and are less likely to be a cure.
So it's not that easy to say what a fair price should be.
Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.